Cencora, Inc. (NYSE:COR) to Post FY2024 Earnings of $13.46 Per Share, Leerink Partnrs Forecasts

Cencora, Inc. (NYSE:COR) – Leerink Partnrs lowered their FY2024 earnings estimates for shares of Cencora in a research note issued on Wednesday, May 1st. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $13.46 per share for the year, down from their prior forecast of $13.51. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Cencora’s current full-year earnings is $13.44 per share. Leerink Partnrs also issued estimates for Cencora’s Q1 2025 earnings at $3.48 EPS, Q3 2025 earnings at $3.72 EPS, Q4 2025 earnings at $3.70 EPS and FY2026 earnings at $16.54 EPS.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 1st. The company reported $3.80 EPS for the quarter, topping the consensus estimate of $3.65 by $0.15. The business had revenue of $68.41 billion during the quarter, compared to analysts’ expectations of $70.60 billion. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The firm’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $3.50 earnings per share.

A number of other equities analysts have also recently issued reports on COR. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. SVB Leerink began coverage on shares of Cencora in a research report on Monday, February 26th. They set an “outperform” rating and a $261.00 price target on the stock. Robert W. Baird lifted their price target on shares of Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. Mizuho upped their price objective on shares of Cencora from $192.00 to $224.00 and gave the company a “neutral” rating in a research note on Monday, February 5th. Finally, Citigroup increased their target price on shares of Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $233.90.

Cencora Stock Up 0.0 %

Shares of NYSE:COR opened at $224.04 on Monday. The firm has a market capitalization of $44.69 billion, a PE ratio of 24.51, a price-to-earnings-growth ratio of 1.61 and a beta of 0.47. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89. Cencora has a 52-week low of $163.37 and a 52-week high of $246.75. The firm has a fifty day moving average of $238.02 and a 200 day moving average of $219.60.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 24th. Investors of record on Friday, May 10th will be issued a dividend of $0.51 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $2.04 dividend on an annualized basis and a yield of 0.91%. Cencora’s dividend payout ratio is presently 22.32%.

Insider Buying and Selling at Cencora

In other news, CEO Steven H. Collis sold 10,754 shares of Cencora stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $67,702,698.24. The sale was disclosed in a filing with the SEC, which is available through this link. In other Cencora news, CEO Steven H. Collis sold 10,754 shares of the company’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $237.48, for a total value of $2,553,859.92. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $67,702,698.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Elizabeth S. Campbell sold 6,977 shares of Cencora stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $238.12, for a total transaction of $1,661,363.24. Following the sale, the executive vice president now directly owns 8,246 shares in the company, valued at approximately $1,963,537.52. The disclosure for this sale can be found here. Insiders sold 4,288,790 shares of company stock valued at $1,009,641,379 in the last 90 days. Insiders own 15.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in COR. Vanguard Group Inc. purchased a new stake in Cencora in the fourth quarter worth $4,212,508,000. Bank of New York Mellon Corp bought a new stake in shares of Cencora during the 1st quarter valued at $291,825,000. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in shares of Cencora in the 1st quarter worth about $238,457,000. Mawer Investment Management Ltd. bought a new position in shares of Cencora in the 1st quarter worth about $191,309,000. Finally, Principal Financial Group Inc. purchased a new position in Cencora during the 1st quarter valued at about $75,916,000. Institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.